US FDA hits Intas Pharma with warning letter; notes data integrity lapses at Ahmedabad plant on December 5, 2023 at 3:34 am

The regulator noted that visual inspectors manipulated particle and other defect counts on records to keep the finished product batches within rejection limits

Leave a comment

Your email address will not be published. Required fields are marked *